本帖最后由 老马 于 2012-1-13 21:20 编辑 3 e9 w& ?: P8 i/ P
: s+ {! `: R; z* D+ @ K爱必妥和阿瓦斯丁的比较
* `; ?- a7 z+ m
6 t" W& t- m- Z& t2 A# qhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/' i, Q5 l2 _" R. Z& n- |3 F; Y
* P8 k9 r7 k+ n: A' g& C0 h# W; o
( M6 P c: \, ~6 Phttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
$ x5 d- [& Q2 O" h f& m" K. s/ }==================================================& k' m6 R( d( [2 s) b3 D9 d
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) X& u& y3 h5 X8 M( y
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
8 o' o2 a7 S; z- G" A, V7 h oResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
. o1 y6 v& h3 ?; C2 q. n6 {
|